11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. This builds on a previous MOU between InSphero and InvitroCue on the in vitro cell-based hepatotoxicity assay.
InvitroCue has a history of pioneering technology and establishing industry firsts for liver-related testing assays through its partnerships with leading pharmaceutical and biotech companies. As part of InvitroCue’s objective to cater for increasing demand for more innovative products and services it has also introduced disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis and malaria. The strategic partnership with InSphero demonstrates the company’s ongoing commitment to deliver customer-centric innovation and best-in-class technological solutions.
“We aim to offer a convenient assay solution for our biopharmaceutical customers to accelerate preclinical drug development and assessment of potential pancreatic toxicity associated with the drugs liver metabolites,” commented Dr. Steven Fang, Executive Director of InvitroCue.
InSphero CEO and co-founder Dr. Jan Lichtenberg said, “The collaboration allows InvitroCue to leverage our next-generation 3D InSight™ Islet Microtissues as part of their toxicity testing services, and establishes important inroads as we continue to grow our business in the important Asia-Pacific Market.”
The press announcement was released on InSphero’s website herein.
– ENDS –
For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
InvitroCue is an Australian-based biotechnology and life science services company. The Company focuses on the commercialisation of its analytics services using cell-based model and imaging based technology. Its cell-based services enable pharmaceutical and cosmetics
companies to refine their drug, ingredient, compound or vaccine discovery efforts. Its digital pathology business offers solutions, including slide scanning and digitisation; image analytics of tissues and cell samples; pathology consultation with board certified pathologists, and telepathology via an online Web-based portal. It provides products and services in the field of in vitro drug metabolism and pharmacokinetic (DMPK), in vitro toxicology and digital pathology utilizing cell-based models and analytics. It offers image analytics services for liver disease applications.
InvitroCue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). InvitroCue has been developed and validated in collaborations with leading pharmaceutical companies and scientific collaborators.
InvitroCue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com